Unraveling the Cardiovascular-Kidney-Metabolic Nexus: Making All Work Together for Kidney Care
Session Description:
This session explores the interconnections between cardiovascular, kidney, and metabolic (CKM) systems. We will review the latest evidence on novel therapeutics for CKD, including GLP-1 RA, endothelin receptor antagonists, and other therapies on the frontier of CKM care. This session will highlight the benefits of GLP-1 RA beyond glycemic control, including cardiovascular and renal protective effects. We will also examine the role of endothelin receptor antagonists (ERAs) as an emerging therapeutic option in CKD management. Finally, we will discuss unique challenges nephrologists face in diagnosing and managing myocardial infarction in the CKD population.
Learning Objectives:
1. Define the cardiovascular-kidney-metabolic syndrome and its pathophysiology, staging, and clinical significance.
2. Evaluate clinical evidence supporting the use of GLP-1 RA and ERAs in CKD management.
3. Discuss practical considerations for the treatment of cardiovascular conditions and reducing cardiovascular risk in patients with CKD.
| Time | Session |
|---|
|
2:15 p.m.
2:33 p.m.
|
Cardiovascular-Kidney-Metabolic Syndrome: What Does it Mean?
IK02-01
KatherineTuttle
Speaker
United StatesUniversity of Washington School of Medicine, Division of Nephrology
|
|
2:33 p.m.
2:51 p.m.
|
GLP-1 RA in Kidney Disease: Beyond T2DM Control
IK02-02
|
|
2:51 p.m.
3:09 p.m.
|
New Frontiers in CKD Therapy: Endothelin Receptor Antagonists
IK02-03
|
|
3:09 p.m.
3:27 p.m.
|
Myocardial Infarction in Kidney Disease - What Should a Nephrologist Know?
IK02-04
|
|
3:27 p.m.
3:45 p.m.
|
Q&A
IK02-05
|